214 related articles for article (PubMed ID: 30064977)
1. Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Schröder L; Fuchs M; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
Blood; 2018 Oct; 132(14):1519-1525. PubMed ID: 30064977
[TBL] [Abstract][Full Text] [Related]
2. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
Strati P; Cheng PTM; Steiner RE; Alcedo Andrade PE; Feng L; Sano D; Rao VA; Singh P; Miranda R; Gunther JR; Pinnix CC; Dabaja BS; Cuglievan B; Xing K; Villa D; Skinnider B; Sehn LH; Connors JM; Nieto Y; Ahmed S; Lee HJ; Savage KJ
Br J Haematol; 2021 Feb; 192(3):560-567. PubMed ID: 33517581
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma.
Akhtar S; Elhassan TAM; Edesa W; Rauf MS; Zahir MN; Maghfoor I
Ann Hematol; 2016 Jan; 95(1):49-54. PubMed ID: 26467917
[TBL] [Abstract][Full Text] [Related]
4. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
Hartmann S; Plütschow A; Mottok A; Bernd HW; Feller AC; Ott G; Cogliatti S; Fend F; Quintanilla-Martinez L; Stein H; Klapper W; Möller P; Rosenwald A; Engert A; Hansmann ML; Eichenauer DA
Am J Hematol; 2019 Nov; 94(11):1208-1213. PubMed ID: 31396979
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Schulz H; Rehwald U; Morschhauser F; Elter T; Driessen C; Rüdiger T; Borchmann P; Schnell R; Diehl V; Engert A; Reiser M
Blood; 2008 Jan; 111(1):109-11. PubMed ID: 17938252
[TBL] [Abstract][Full Text] [Related]
6. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG.
Binkley MS; Rauf MS; Milgrom SA; Pinnix CC; Tsang R; Dickinson M; Ng AK; Roberts KB; Gao S; Balogh A; Ricardi U; Levis M; Casulo C; Stolten M; Specht L; Plastaras JP; Wright C; Kelsey CR; Brady JL; Mikhaeel NG; Hoppe BS; Terezakis SA; Picardi M; Della Pepa R; Kirova Y; Akhtar S; Maghfoor I; Koenig JL; Jackson C; Song E; Sehgal S; Advani RH; Natkunam Y; Constine LS; Eich HT; Wirth A; Hoppe RT
Blood; 2020 Jun; 135(26):2365-2374. PubMed ID: 32211877
[TBL] [Abstract][Full Text] [Related]
7. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
Josting A; Franklin J; May M; Koch P; Beykirch MK; Heinz J; Rudolph C; Diehl V; Engert A
J Clin Oncol; 2002 Jan; 20(1):221-30. PubMed ID: 11773173
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
Bröckelmann PJ; Müller H; Gillessen S; Yang X; Koeppel L; Pilz V; Marinello P; Kaskel P; Raut M; Fuchs M; Borchmann P; Engert A; von Tresckow B
Leukemia; 2022 Mar; 36(3):772-780. PubMed ID: 34628472
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Fuchs M; Sasse S; Baues C; Böll B; von Tresckow B; Diehl V; Borchmann P; Engert A
J Clin Oncol; 2020 Mar; 38(7):698-705. PubMed ID: 31626571
[TBL] [Abstract][Full Text] [Related]
12. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
[TBL] [Abstract][Full Text] [Related]
13. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
Eichenauer DA; Engert A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
[TBL] [Abstract][Full Text] [Related]
14. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
[TBL] [Abstract][Full Text] [Related]
15. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
[TBL] [Abstract][Full Text] [Related]
16. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
[TBL] [Abstract][Full Text] [Related]
17. High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.
Akhtar S; Montoto S; Boumendil A; Finel H; Masszi T; Jindra P; Nemet D; Fuhrmann S; Beguin Y; Castagna L; Ferrara F; Capria S; Malladi R; Moraleda JM; Bloor A; Ghesquières H; Meissner J; Sureda A; Dreger P
Am J Hematol; 2018 Jan; 93(1):40-46. PubMed ID: 28971503
[TBL] [Abstract][Full Text] [Related]
18. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
20. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]